RIF! - Rejstřík informací Fóra Věda žije!

RIV/61989592:15310/13:33147716 - A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care


Údaje o výsledku

Identifikační kód: RIV/61989592:15310/13:33147716
Název v původním jazyce: A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care
Název česky:
Druh: J - Článek v odborném periodiku
Jazyk: eng - angličtina
Obor: FR - Farmakologie a lékárnická chemie
Rok uplatnění: 2013
Kód důvěrnosti: S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
Počet tvůrců: 28
Počet domácích tvůrců: 1
Tvůrce: Kast, Richard E
Tvůrce: Boockvar, John A
Tvůrce: Brüning, Ansgar
Tvůrce: Cappello, Francesco
Tvůrce: Chang, Wen-Wei
Tvůrce: Cvek, Boris
Tvůrce: Dou, Q Ping
Tvůrce: Duenas-Gonzalez, Alfonso
Tvůrce: Efferth, Thomas
Tvůrce: Focosi, Daniele
Tvůrce: Ghaffari, Seyed H
Tvůrce: Karpel-Massler, Georg
Tvůrce: Ketola, Kirsi
Tvůrce: Khoshnevisan, Alireza
Tvůrce: Keizman, Daniel
Tvůrce: Magné, Nicolas
Tvůrce: Marosi, Christine
Tvůrce: Mcdonald, Kerrie
Tvůrce: Munoz, Miguel
Tvůrce: Paranjpe, Ameya
Tvůrce: Pourgholami, Mohammad H
Tvůrce: Sardi, Iacopo
Tvůrce: Sella, Avishay
Tvůrce: Srivenugopal, Kalkunte S
Tvůrce: Tuccori, Marco
Tvůrce: Wang, Weiguang
Tvůrce: Wirtz, Christian R
Tvůrce: Halatsch, Marc-Eric

Údaje blíže specifikující výsledek

Popis v původním jazyce: To improve prognosis in recurrent glioblastoma we developed a treatment protocol based on a combination of drugs not traditionally thought of as cytotoxic chemotherapy agents but that have a robust history of being well-tolerated and are already marketed and used for other non-cancer indications. Focus was on adding drugs which met these criteria: a) were pharmacologically well characterized, b) had low likelihood of adding to patient side effect burden, c) had evidence for interfering with a recognized, well-characterized growth promoting element of glioblastoma, and d) were coordinated, as an ensemble had reasonable likelihood of concerted activity against key biological features of glioblastoma growth. We found nine drugs meeting these criteria and propose adding them to continuous low dose temozolomide, a currently accepted treatment for relapsed glioblastoma, in patients with recurrent disease after primary treatment with the Stupp Protocol. The nine adjuvant drug regimen, Coordinated Undermining of Survival Paths, CUSP9, then are aprepitant, artesunate, auranofin, captopril, copper gluconate, disulfiram, ketoconazole, nelfinavir, sertraline, to be added to continuous low dose temozolomide. We discuss each drug in turn and the specific rationale for use- how each drug is expected to retard glioblastoma growth and undermine glioblastoma's compensatory mechanisms engaged during temozolomide treatment. The risks of pharmacological interactions and why we believe this drug mix will increase both quality of life and overall survival are reviewed.
Popis česky:
Klíčová slova:
Název periodka: Oncotarget
Rozsah stran:
ISSN: 1949-2553
Svazek periodika: 4
Číslo periodika v rámci uvedeného svazku: 4
Stát vydavatele periodika: US - Spojené státy americké
Počet stran výsledku: 29
DOI:

Údaje o tomto záznamu o výsledku

Předkladatel: Univerzita Palackého v Olomouci / Přírodovědecká fakulta (IČO: 61989592)
Dodavatel: MSM
Rok sběru: 2014
Systémové označení dodávky dat: RIV14-MSM-15310___/01:1
Kontrolní kód: [5C43D90CB497]